{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Infection+%28HIV%29&page=55",
    "query": {
      "condition": "Human Immunodeficiency Virus Infection (HIV)",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 1709,
    "total_pages": 171,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Infection+%28HIV%29&page=56&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Infection+%28HIV%29&page=54&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T21:59:00.322Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02881762",
      "title": "Maraviroc Efficacy for Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-06-01",
      "completion_date": "2019-03-27",
      "has_results": true,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02881762"
    },
    {
      "nct_id": "NCT00244803",
      "title": "Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 101,
      "start_date": "2005-01",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2016-08-31",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244803"
    },
    {
      "nct_id": "NCT00798265",
      "title": "A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus",
        "Human Papillomavirus- 6, 11, 16, 18",
        "Adolescent",
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Gardasil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Survey",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "BEHAVIORAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "12 Years to 26 Years"
      },
      "enrollment_count": 26,
      "start_date": "2009-06-29",
      "completion_date": "2013-02-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798265"
    },
    {
      "nct_id": "NCT01860807",
      "title": "Trial of Ibudilast for Methamphetamine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Methamphetamine Dependence",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Ibudilast",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2013-07",
      "completion_date": "2017-12-31",
      "has_results": true,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860807"
    },
    {
      "nct_id": "NCT03886701",
      "title": "Doravirine, Rifapentine and Isoniazid Interaction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Latent Tuberculosis",
        "Human Immunodeficiency Virus",
        "Rifamycins Causing Adverse Effects in Therapeutic Use",
        "Drug Interaction Potentiation"
      ],
      "interventions": [
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        },
        {
          "name": "Rifapentine (RPT)",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid (INH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter K. Kraft",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 11,
      "start_date": "2019-04-22",
      "completion_date": "2019-05-20",
      "has_results": true,
      "last_update_posted_date": "2020-03-27",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03886701"
    },
    {
      "nct_id": "NCT05099965",
      "title": "Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "HIV Infections",
        "Vaccine"
      ],
      "interventions": [
        {
          "name": "CMV-MVA Triplex",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2021-11-02",
      "completion_date": "2025-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099965"
    },
    {
      "nct_id": "NCT03666871",
      "title": "CCR5-modified CD4+ T Cells for HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "SB-728-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Expanded unmodified autologous CD4+ T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-06-12",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03666871"
    },
    {
      "nct_id": "NCT02808949",
      "title": "Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dapivirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "International Partnership for Microbicides, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2015-02",
      "completion_date": "2018-03-03",
      "has_results": false,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808949"
    },
    {
      "nct_id": "NCT02345252",
      "title": "Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "FTC/RPV/TAF",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 632,
      "start_date": "2015-01-26",
      "completion_date": "2019-01-09",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345252"
    },
    {
      "nct_id": "NCT02778204",
      "title": "Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "3 Days",
        "sex": "ALL",
        "summary": "Up to 3 Days"
      },
      "enrollment_count": 47,
      "start_date": "2017-06-05",
      "completion_date": "2019-11-20",
      "has_results": true,
      "last_update_posted_date": "2022-01-04",
      "last_synced_at": "2026-10-31T21:59:00.322Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02778204"
    }
  ]
}